“Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis”, J of Skin, vol. 1, no. 3.1, p. s10, Oct. 2017, doi: 10.25251/skin.1.supp.9.